The Low Carb Diabetic

Promoting a low carb high fat lifestyle for the safe control of diabetes. Eat whole fresh food, more drugs are not the answer.


Welcome to the Low Carb Diabetic forum,have you signed up yet? if not then sign up and join us in the low carb community today!

    Rethinking the appraisal and approval of drugs for type 2 diabetes

    Share
    avatar
    graham64
    Member

    Status :
    Online
    Offline

    Male Posts : 2855
    Join date : 2014-08-10
    Location : Lancs

    Rethinking the appraisal and approval of drugs for type 2 diabetes

    Post by graham64 on Sun Oct 11 2015, 22:01

    Huseyin Naci and colleagues call for improvements in the regulatory standards for licensing, reimbursing, and adopting new preventive drugs to ensure that treatments for type 2 diabetes really benefit patients

    The aim of drug regulation is to ensure that only effective and safe treatments reach patients. Ideally, regulatory decisions are based on good quality data from large trials measuring real world, patient centred outcomes. Licensing agencies, however, routinely approve treatments on the basis of small placebo controlled trials evaluating short term, surrogate endpoints in selected populations. Consequently, medicines are commonly prescribed without good quality data on their long term benefits and harms.1 2 Current licensing standards are inadequate to predict the real world therapeutic value of new medications.3

    This is particularly problematic for preventive treatments given to large populations, which should be subject to a high standard of proof of benefit and absence of appreciable harm. These drugs present interesting challenges because, firstly, the real world benefits often take many years to arise and, secondly, those benefits are often modest, although clinically important. Trials should quantify the benefits and harms for the various populations that will use these drugs, ideally using prespecified subgroups of sufficient size. This would provide clinicians and patients with dependable knowledge for shared decision making. In this article we use the example of drugs for type 2 diabetes to highlight the shortcomings of the evidence standards for licensing, reimbursing, and adopting new preventive drugs and suggest some solutions.


    Time to curb regulatory enthusiasm for “timely market access”

    Blood glucose lowering is the only benchmark used by regulatory agencies to grant market approval to antidiabetic drugs (box 1). There are more than 30 antidiabetic drugs on the market, and for most we have insufficient evidence from randomised trials about their long term clinical benefits or harms.

    http://www.bmj.com/content/351/bmj.h5260

    Can't access the full article but I hope this is going someway to reassess the effects of these new drugs


    _________________
    I'm a skinny T2 diagnosed 4/4/2008, a high calorie LCHF diet and one metformin a day A1c 6.2 and no complications.

    Proving the LowCarb sceptics wrong for over nine years,

    Not all cherubs are Angels  Wink nor all diabetics Bonkers  Rolling Eyes

      Current date/time is Fri Jul 21 2017, 07:50